E

Evvy

At-home metagenomic vaginal microbiome sequencing

Vice President Finance

Full-Time
No salary listed
Expert
New York, NY, USA
HybridFour days on-site per week; Wednesdays are remote.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • Head-of or Vice President-level experience leading a Finance function at a startup, ideally with direct oversight of strategic finance, financial planning and analysis, and accounting.
  • A combination of formal finance training, such as investment banking or corporate finance, and hands-on operating experience at a fast-growing startup.
  • A track record of building financial infrastructure and processes from the ground up, including systems implementations, audit readiness, or scaling a finance team.
  • Experience managing investor relationships.
  • Comfort owning People or Human Resources alongside finance, even without a formal Human Resources background.
  • Ability to set strategy and execute hands-on.
  • Ability to communicate clearly and credibly at the board level and in operational details.
  • Ability to operate with high ownership and ambiguity and bring structure to undefined problems.
  • Willingness to own finance, accounting, and people functions rather than a single narrow area.
Responsibilities
  • Lead revenue forecasting and company-wide budgeting, including hiring plans and resource allocation.
  • Build and maintain pricing and business-case models for new products, provider relationships, and partnerships.
  • Own capital strategy planning and investor financial reporting and serve as a key contact for existing and prospective investors.
  • Oversee the Controller and accounting function, including month-end close, Generally Accepted Accounting Principles compliance, and tax, and bring the company to audit-ready status.
  • Lead implementation and adoption of an enterprise resource planning system and inventory management system.
  • Own the systems roadmap for finance and operations.
  • Oversee bill pay, cash management, sales tax, insurance renewals, and vendor relationships with banking, tax, and insurance providers.
  • Bring in-house capabilities such as Human Resources Information Systems and payroll at appropriate growth stages.
  • Oversee the People Operations Manager and People operations, including recruiting infrastructure, onboarding, Human Resources inquiries, benefits and compliance, office management, and operational support for the in-person team.
  • Partner with the Chief Executive Officer on performance management, leveling, and calibration processes.
  • Partner with the Chief Executive Officer on board meeting preparation, investor relations, and recurring high-priority finance and people workstreams.
  • Represent finance and people in company-wide planning cycles, key performance indicator reviews, and All Hands meetings.
  • Provide judgment and leverage in ambiguous, cross-functional situations involving finance, people, or operations.
Desired Qualifications
  • Prior experience through a company exit, such as an acquisition or initial public offering.
  • Experience with payor coverage, reimbursement, or revenue cycle management.
  • Venture capital experience, ideally with exposure to consumer or digital health.

About the company

E

Evvy

View
Website

Evvy provides an at-home, CLIA- and CLEP-certified metagenomic sequencing test to analyze the vaginal microbiome, with results reviewed by clinicians and guided by EvvyAI, an AI advisor that turns molecular findings into practical care guidance. Patients collect samples at home, send them to a lab, and receive personalized care pathways based on their microbiome profile and symptoms. The company differentiates itself by pairing clinician-reviewed, at-home mNGS testing with AI-driven recommendations, supported by peer-reviewed research and a large real-world dataset, plus collaborations on fertility and IVF studies. Its goal is to close the gender health data gap by linking microbiome biology with symptoms, treatments, and outcomes to enable precision medicine in women's health.

Company Size

51-200

Company Stage

Series B

Total Funding

$59M

Headquarters

New York City, New York

Founded

2020

Get referred to Evvy

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 15, 2026 Series B added $40 million from Catalio, US Fertility, and Labcorp.
  • Evvy's fertility study with US Fertility started in 2025 and deepened in 2026.
  • The UTI+ Test, launched December 2025, expands revenue beyond vaginal microbiome testing.

What critics are saying

  • Fertility and cancer links remain association-heavy; 2026 payoffs depend on causal validation.
  • Juno Bio's July 2026 sequencing push attacks Evvy's core diagnostic niche directly.
  • If FDA or payers demand randomized outcomes data, Evvy's DTC economics break.

What makes Evvy unique

  • Evvy's 2021 mNGS swab spans 700-plus microbes with CLIA and NYS CLEP review.
  • The dataset reached 100,000 patients and 3,000 practitioners by September 2026.
  • EvvyAI launched May 2026, turning female-specific microbiome data into clinician-reviewed guidance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • Professional Development Budget
  • Paid Parental Leave
  • Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-1%

2 year growth

-1%
HYPERURANIOS
Sep 18th, 2026
September 2026 funding rounds total $1.5bn across AI, robotics and biotech.

September 2026 funding rounds total $1.5bn across AI, robotics and biotech. Multiple late-stage rounds raised large sums for AI models, robot chips and biotech platforms, highlighting investor focus on advanced computation and health data. Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here. Artificial intelligence. Seattle AI lab Nuance Labs raised a $50 million Series A, led by Lightspeed Venture Partners and joined by Accel, South Park Commons, NVIDIA and Define Ventures, to accelerate development of its full-duplex foundation model that perceives and generates real-time human expression for sales, customer service and education applications [3]. Hang Ten Systems, founded by former Infosys CEO Vishal Sikka, secured an additional $53 million in seed funding, bringing total capital to $85 million; the round was led by Xora (backed by Temasek) with Mayfield, Aramco Ventures, Intel CEO Lip-Bu Tan, Micron CEO Sanjay Mehrotra and Yahoo co-founder Jerry Yang also participating, to expand its AI-enabled enterprise engineering platform and global sales teams [7]. Robotics. D-Robotics closed a $400 million Series C, the largest Chinese robotics round in four years, led by Mirae Asset and Meituan with a strategic investment from a leading global internet firm and follow-on funding from existing shareholders; the capital will expand the Sunrise chip family across performance tiers and build a full software platform covering data collection, simulation and deployment, as the company reported revenue growth of several times year-on-year and cumulative chip shipments exceeding 8 million units, with its S600 chip adopted by more than 20 embodied-AI customers [1][2][4][6]. Genetic engineering. Evvy, a New York women's-health company that sequences the vaginal microbiome via an at-home swab, secured an oversubscribed $40 million Series B led by Catalio Capital Management, joined by Rethink Impact, Muse Capital, Alumni Ventures and existing backers such as LabCorp Venture Fund and General Catalyst, to fund a prospective IVF study and AI diagnostic models built on its dataset [5]. Matisse Pharmaceuticals B.V., a Dutch clinical-stage biotech developing isupartob sodium for sepsis, completed a €14 million Series A financing involving existing shareholders, Brightlands Venture Partners, LIOF and other institutional investors, with proceeds earmarked for a Phase 2 trial and related regulatory and manufacturing activities [8].

Microbiome Times Magazine
Sep 16th, 2026
Evvy raises $40M Series B to scale ai-powered precision diagnostics & care platform for women's health.

Evvy raises $40M Series B to scale ai-powered precision diagnostics & care platform for women's health. The oversubscribed round, led by Catalio Capital Management, will fund clinical validation of new AI diagnostic models as Evvy expands beyond vaginal microbiome testing into broader women's health Evvy, the pioneering precision medicine company for women's health, today announced an oversubscribed $40 million Series B led by Catalio Capital Management. Since its founding in 2021, the company has built the world's largest proprietary, clinical-grade dataset on the vaginal microbiome and women's health outcomes - and the machine learning engine, EvvyAI, that interprets large-scale biological data to transform patient care. This round will fund the validation of a new generation of AI-driven diagnostic and care models across women's health, starting with fertility. The Series B funding round includes new investors Catalio Capital Management, Rethink Impact, Muse Capital, and Alumni Ventures, alongside existing investors LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures. Founded by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy is the leading vaginal microbiome platform, serving over 100,000 patients and 3,000 practitioners with comprehensive at-home testing, personalized treatment, and longitudinal biomarker tracking. Every Evvy test is powered by CLIA-certified, NYS CLEP-approved metagenomic sequencing; ordered and interpreted by licensed clinicians; and matched with prescription treatment plans tailored to each patient's results and health history where relevant. Evvy's proprietary dataset and insights compound with every test, and their platform has already led to 13 peer-reviewed publications and abstracts, the identification of novel BV Subtypes, and the discovery of hundreds of previously uncatalogued vaginal microbiome genomes. The majority of patients come to Evvy with active vaginal symptoms or fertility challenges that standard-of-care testing has failed to explain. In the U.S., vaginal symptoms are a leading reason women seek healthcare, yet patients face 50%+ misdiagnosis rates and 60%+ recurrence rates in traditional care settings. Licensed clinicians leveraging Evvy's platform and EvvyAI are able to deliver a diagnosis to 90%+ of symptomatic patients and drive a ~50%+ reduction in bacterial vaginosis (BV) recurrence through targeted, data-driven treatment protocols. The significant improvements to patient outcomes have been validated in peer-reviewed research. Jacob Vogelstein, Co-Founder and Managing Partner at Catalio Capital Management, stated: "We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it." He continued: "Its combination of proprietary data, clinical evidence, and a growing biomarker discovery engine creates an entirely new foundation for precision women's healthcare. We believe Evvy is building the data platform that will define this category for decades to come." With the new capital, Evvy will pursue clinical validation of new EvvyAI-powered diagnostic and care models across a set of women's health conditions that collectively cost the healthcare system more than $180 billion in underserved outcomes - and expand distribution through physicians and partner channels. Evvy will also continue its collaboration with US Fertility, the nation's largest network of fertility clinics, to advance research on the role of the vaginal microbiome in fertility and reproductive health. Priyanka Jain, Co-Founder and CEO of Evvy, remarked: "Women hear 'unexplained' constantly - unexplained infertility, unexplained recurrence, unexplained pain. It's stated like a diagnosis, when it really just means medicine wasn't built to measure female biology. We set out to build the datasets and AI infrastructure that precision medicine in women's health has been missing. The vaginal microbiome is a perfect example of this - a powerful, overlooked biomarker impacting fertility, preterm birth, gynecological cancers, and more. Evvy is building the evidence, infrastructure, and partnerships needed to make precision, data-driven care the standard for women's health." About Evvy. Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy's groundbreaking Vaginal Health Test is the world's only CLIA-certified, CLEP-approved mNGS test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways, Evvy provides 100,000+ patients with data-driven, personalized care for vaginal infections, fertility, menopause, and more. Evvy is backed by 15+ peer-reviewed publications & abstracts, including validation of their novel test methodology and a study demonstrating significant improvements to patient outcomes. Evvy has built the world's largest dataset on the vaginal microbiome and is pioneering research to improve outcomes across the female lifespan.

ChannelNews
Sep 15th, 2026
Evvy raises $40M as it seeks to further women's health research with vaginal microbiome data.

Evvy raises $40M as it seeks to further women's health research with vaginal microbiome data. Women's health company Evvy announced Tuesday a $40 million Series B led by Catalio Capital Management. Evvy's $40 million Series B funding round, led by Catalio Capital Management, signals a significant investment in women's health research, specifically focusing on the vaginal microbiome. This area of study has been historically underfunded and understudied, despite its critical role in overall women's health. By gathering and analyzing vaginal microbiome data, Evvy aims to shed light on the complex relationships between the microbiome, women's health, and various conditions such as infertility, menstrual health, and pregnancy complications. The investment in Evvy reflects a growing recognition of the importance of women's health research and the potential for data-driven insights to drive innovation in this space. The vaginal microbiome is a rich source of data that can help researchers better understand the intricacies of women's health and develop more effective treatments. With this funding, Evvy is poised to expand its research capabilities and develop new products and services that can improve women's health outcomes. As the healthcare industry continues to shift towards personalized medicine, Evvy's work in this area could have far-reaching implications. As Evvy moves forward with its research and product development, it's worth watching how the company navigates the complex regulatory landscape surrounding women's health and microbiome research. Additionally, investors and industry observers will be keeping a close eye on Evvy's ability to translate its research findings into tangible products and services that can improve women's health outcomes. With the growing emphasis on women's health and precision medicine, Evvy's progress will be an important indicator of the potential for innovation in this space. Originally reported by techcrunch.com. ChannelNews adds analysis for technology readers. Originally reported by techcrunch.com. ChannelNews curates and briefs the technology stories that matter. Its editorial policy

Tech Funding News
Sep 15th, 2026
Evvy raises $40M from Catalio Capital to take its vaginal microbiome data into fertility.

Evvy raises $40M from Catalio Capital to take its vaginal microbiome data into fertility. September 15, 2026 * Evvy has raised a $40 million Series B led by Catalio Capital Management to push its vaginal microbiome platform into fertility diagnostics. * The New York company has built a dataset from more than 100,000 patients to train EvvyAI, its machine-learning engine for biomarker discovery. * The round brings Evvy's total funding to nearly $60 million, following a $14 million Series A in September 2023 led by Left Lane Capital. For years, the patients who came to Priyanka Jain with recurring infections or unexplained infertility had heard some version of the same sentence from a doctor: no clear cause found. Jain built Evvy to replace that shrug with data, starting with the vaginal microbiome. Now the startup is chasing a bigger target. Evvy has raised a $40 million Series B led by Catalio Capital Management to expand into fertility. The round is oversubscribed and includes new investors US Fertility, through its Innovation Fund, Rethink Impact, Muse Capital and Alumni Ventures, alongside returning backers General Catalyst, Left Lane Capital, Labcorp Venture Fund, BBG Ventures, Amboy Street Ventures, Ingeborg and Foreground Capital. It brings Evvy's total funding to nearly $60 million across three rounds since 2021. From vaginal health to fertility. Priyanka Jain co-founded Evvy in New York in 2021 alongside Laine Bruzek and Pita Navarro, all three women, after Jain spent four years as head of product at pymetrics, an AI hiring startup. Evvy's first product was an at-home vaginal microbiome test using metagenomic sequencing, built to catch what standard swab tests miss. It works by sequencing more than 700 bacteria and fungi from a single sample, then routing results through licensed clinicians who can prescribe treatment. That data set, now drawn from more than 100,000 patients and 3,000 practitioners, feeds EvvyAI, the company's machine-learning platform. Evvy says the work has produced 13 peer-reviewed publications, identified new bacterial vaginosis subtypes and led to a diagnosis for more than 90% of symptomatic patients, with targeted treatment cutting BV recurrence by roughly half. Competition heats up around women's health data. Evvy is entering a broader women's health market that is attracting increasingly large rounds. Juno Bio, another vaginal microbiome diagnostics company, raised $3.8 million in July 2026 to expand its sequencing platform and open a CLIA-certified women's health lab. Maven Clinic raised $125 million in 2024 at a $1.7 billion valuation, while Midi Health raised $100 million in February 2026 at a valuation above $1 billion. Evvy's pitch is that it owns the underlying diagnostic layer those broader platforms don't. Catalio, the lead investor, has a pattern of backing diagnostics plays: its portfolio includes PinkDx, a $40 million Series A for gynecological cancer diagnostics, alongside larger biotech bets like Odyssey Therapeutics and Imperative Care. "We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it," said Jacob Vogelstein, co-founder and managing partner at Catalio Capital. Jain frames the opportunity around a word she says patients hear too often: "Women hear 'unexplained' constantly - unexplained infertility, unexplained recurrence, unexplained pain. It's stated like a diagnosis, when it really just means medicine wasn't built to measure female biology." What's next? The women's health funding gap is well documented: the McKinsey Health Institute estimates that closing it could add $1 trillion to annual global GDP by 2040, largely because so little clinical data exists on conditions that affect women specifically. Whether a data company can out-execute better-funded virtual-care platforms at their own game, once it moves past its niche, is the open question this round doesn't answer.

Beauty Independent
Sep 15th, 2026
Evvy raises $40M to make vaginal microbiome testing routine in women's healthcare

Evvy has raised $40 million in an oversubscribed Series B round led by Catalio Capital to expand its vaginal microbiome platform into reproductive healthcare, focusing on fertility and IVF. The round included U.S. Fertility's Innovation Fund, Labcorp Venture Fund, and existing investors including General Catalyst and Left Lane Capital, bringing total funding to nearly $60 million. The company has served over 100,000 patients and partnered with 3,000 healthcare practitioners, building what it describes as the world's largest proprietary dataset on the vaginal microbiome. Ninety-six percent of patients contribute data anonymously to clinical research. Evvy's at-home Vaginal Health Test analyses over 700 bacteria and fungi using metagenomic sequencing, priced at $159 per test. The funding will scale EvvyAI, the company's data and AI platform underlying its diagnostic services. CEO Priyanka Jain aims to make vaginal microbiome screening routine preventive care, comparable to Pap smears, addressing areas where women's health research has historically been limited.